Here is the design of a clinical trial:

Official Title: Team Approach to Polypharmacy Evaluation and Reduction Randomized Controlled Trial

Included conditions:
- Multi-morbidity
- Medication Therapy Management
- Polypharmacy

Study Armgroups:
- {'label': 'TAPER', 'type': 'EXPERIMENTAL', 'description': 'The intervention is medication reduction. This arm is comprised of:\n\n1. Medication reconciliation\n2. Identification of patient priorities for care\n3. Identification of medications that are potentially appropriate for discontinuation/dose reduction\n4. Linked pharmacist/family physician consultations with patient to discuss medication with intention to reduce\n5. Identification of medications for trial of discontinuation/dose reduction (shared decision making)\n6. Pause of medication and clinical monitoring', 'interventionNames': ['Other: Medication reduction']}
- {'label': 'Control', 'type': 'NO_INTERVENTION', 'description': 'Standard of Care as wait list control. Control group will be offered intervention as part of usual clinical care at 6 months.'}

Interventions:
- {'type': 'OTHER', 'name': 'Medication reduction', 'description': 'Systematic approach to reduction in polypharmacy.', 'armGroupLabels': ['TAPER'], 'otherNames': ['Medication discontinuation/dose reduction']}

Primary Outcomes:
- {'measure': 'Successful discontinuation (mean difference in number of medications)', 'description': 'Difference in mean number of medications', 'timeFrame': 'Baseline, 6 months'}

Please estimate the sample size based on the assumption: 
Power set at 80%, significance level 5%, 10% attrition rate.
Sample size
        Sample size calculations for the RCT were performed by the team biostatistician (LT). We used data from our feasibility study to estimate sample size: mean number of medications of 7.7, a post-intervention reduction in mean (standard deviation) of 4.2 (Â± 2.5). There was consensus from the expert international polypharmacy advisory group that a mean reduction of 2 medications is clinically important [42].
        A sample size of at least 160 per group is sufficient to detect a difference in mean number of medications of 2, assuming a starting mean of 7 and a static control group (power set at 80%, significance level 5%). It will also allow detection of an absolute difference in the proportion of patients with drug-related side effects of 15% (10% versus 25%) and provides adequate power for subgroup analysis for the primary outcome if proportions are 40% or more. Allowance has been made for 10% attrition; therefore, the final minimum recruitment target is 180 per group (total N = 360).